Immunotherapy for Alzheimer's disease: hoops and hurdles
about
Intravenous immunoglobulin for Alzheimer's diseaseAmyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta poresAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTThe Role of Inflammatory Mediators in the Pathogenesis of Alzheimer's DiseaseAlzheimer disease immunotherapeutics: then and nowAAV2/1 CD74 Gene Transfer Reduces β-amyloidosis and Improves Learning and Memory in a Mouse Model of Alzheimer's Disease.Complex regulation of γ-secretase: from obligatory to modulatory subunitsImmunotherapeutic approaches for Alzheimer's diseaseDrug candidates in clinical trials for Alzheimer's disease.Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice.Novel immunological approaches for the treatment of Alzheimer's disease.Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonistAnti-aβ oligomer IgG and surface sialic acid in intravenous immunoglobulin: measurement and correlation with clinical outcomes in Alzheimer's disease treatment.Engineered antibody therapies coming of age for aging brainsDAP12 Stabilizes the C-terminal Fragment of the Triggering Receptor Expressed on Myeloid Cells-2 (TREM2) and Protects against LPS-induced Pro-inflammatory Response.An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect.Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington's diseaseA fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Continuous vaccinations of 4Aβ1-15 induces specific fluctuation of inflammatory factors accompany with pathologic alterations alleviation in APP/PS1 mice.Signaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Appoptosin interacts with mitochondrial outer-membrane fusion proteins and regulates mitochondrial morphologyInhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies.Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's DiseaseImmunization with Small Amyloid-β-derived Cyclopeptide Conjugates Diminishes Amyloid-β-Induced Neurodegeneration in MiceThe mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradationPre-amyloid oligomers budding:a metastatic mechanism of proteotoxicity.Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis.Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.BACE1 inhibitor drugs in clinical trials for Alzheimer's disease.
P2860
Q24188215-8F1AEA08-5F81-4DDA-9386-80EADB9B88F9Q26738355-5C759836-B73C-47C6-82CB-CF73C0DB397FQ26740418-4E5F3252-D236-49DF-8104-0F48FAEA3457Q26749755-880AFA5D-3E8F-44CF-B91F-2EA43ABAEF2FQ26781815-D345F806-2D72-4113-8FDB-D66FD8C2EF77Q27001031-1F2CE56B-438E-438D-83E3-2D4A325F188FQ27318148-DE9B7412-3FC4-4EED-9A40-330D010B4447Q28080576-02AE33D4-FD70-400C-AF61-413C2D4E0BE5Q28081278-23956CED-D66C-42C7-8031-65E0AD5F5E3BQ33916749-41E9543F-040F-42BA-A724-500418877FBEQ34240270-74AC218B-A2A9-445D-8918-29A61228E8FEQ34562675-65264149-4F86-46F2-84F1-8C60883C7330Q35058359-E37D79E6-49DB-4B7B-B80D-74D751BE7627Q35137114-AE0A3F09-BFCB-481E-B58C-BBFC80544D37Q35590968-82A5218A-9717-4B28-AC54-6D7AA4AFD8B9Q35596571-262E423E-FBC7-4691-B8F6-50266AC614D6Q35860733-2B317555-0BBC-452C-81BB-B4A219EEAA83Q36002121-DAEA91AB-0546-42E0-9767-ABB4BE62200CQ36142398-3EE0BCFE-83DF-44A1-8E92-F4BD010B1B30Q36240389-DBA31368-4E5D-4B51-BC30-0BC21DCAC7DDQ36388994-86BDAAB4-0325-4DC3-B45A-5712E6A26185Q36483870-D2BAECB0-716C-448A-A34F-91A8E2811828Q36558485-F7374A2E-37F1-432A-AEDC-B90B9B81A1E4Q36743958-CBE2898F-FA54-4C66-A9BA-C4137F8AEE71Q36869427-F34021D5-4C61-4471-8AF3-E8BAFC00F9B1Q36899566-7E29194F-5719-4788-BE2A-473C778B969EQ37031396-A70BC63C-D75E-4EA3-9E7E-37D284FD3897Q37044127-AA465E8D-427C-42A9-94BE-279DB074CE6DQ37053799-13A324FB-8D9B-4C2B-92E7-EFCCA1BAE9AAQ37085168-A37F0BD5-F182-44E5-A966-0381BEF2652FQ37360313-61AC8DAB-2104-456E-BC47-140E24F336ADQ37501943-55A56022-45F3-46D6-9486-8B04B8842940Q37604055-480745E6-D5DF-4ED7-AD1A-D8CB2AA989C8Q38184618-70D64430-B5BE-4EBB-AE29-5ACA89DCE575Q38187861-7DFBDF7A-F86F-46CB-83F7-E6E0BC858047Q38195641-F2953BFC-12E2-4DB4-B8EC-7AE19874CFD6Q38224958-1338DC36-A81D-4446-8E43-3D9B6E7C51A9Q38235780-32B44CCB-B15F-4929-8DFF-6C334E3E8FDDQ38240609-0DE2D026-3E23-43E5-A628-670736A91207Q38332419-ABC7BB01-3936-4303-A3E3-1FC055AD5D02
P2860
Immunotherapy for Alzheimer's disease: hoops and hurdles
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Immunotherapy for Alzheimer's disease: hoops and hurdles
@ast
Immunotherapy for Alzheimer's disease: hoops and hurdles
@en
Immunotherapy for Alzheimer's disease: hoops and hurdles
@nl
type
label
Immunotherapy for Alzheimer's disease: hoops and hurdles
@ast
Immunotherapy for Alzheimer's disease: hoops and hurdles
@en
Immunotherapy for Alzheimer's disease: hoops and hurdles
@nl
prefLabel
Immunotherapy for Alzheimer's disease: hoops and hurdles
@ast
Immunotherapy for Alzheimer's disease: hoops and hurdles
@en
Immunotherapy for Alzheimer's disease: hoops and hurdles
@nl
P2860
P3181
P356
P1476
Immunotherapy for Alzheimer's disease: hoops and hurdles
@en
P2093
Cynthia A Lemere
P2860
P2888
P3181
P356
10.1186/1750-1326-8-36
P407
P5008
P577
2013-10-22T00:00:00Z
P5875
P6179
1038804536